Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for DSP Process Validation Sampling – V 2.0

Posted on By


Biosimilars: SOP for DSP Process Validation Sampling – V 2.0


Standard Operating Procedure for DSP Process Validation Sampling in Biosimilar Manufacturing

Department Biosimilars
SOP No. SOP/BS/190/2025
Supersedes SOP/BS/190/2022
Page No. Page 1 of 9
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define a standardized and GMP-compliant procedure for collecting, handling, and documenting samples for process validation during downstream processing (DSP) of biosimilars.

2. Scope

This SOP applies to all validation batches of biosimilar products undergoing downstream unit operations, including chromatography, filtration, ultrafiltration/diafiltration, and bulk holding, where sampling is necessary for demonstrating process consistency and robustness.

3. Responsibilities

  • Production: Execute sampling at designated stages, label and transfer samples as per plan.
  • QC: Analyze validation samples and report deviations.
  • QA: Review validation sample records and ensure sampling plan compliance.
  • Validation Team: Design sampling plan and define critical process parameters (CPPs) and acceptance criteria.

4. Accountability

The Head of Manufacturing and the Head of Quality Assurance are jointly accountable for ensuring the completeness, accuracy, and regulatory compliance of DSP validation sampling activities.

5. Procedure

5.1 Sampling Plan Development

  1. Define sampling points based on risk assessment and criticality of DSP operations (e.g., column load/unload, filtration start/end, UF/DF inlets/outlets).
  2. Document plan in the approved Process Validation Protocol (PVP), including:
    • Sampling frequency (e.g., hourly, batch-specific)
    • Sample size and container
    • Required tests (purity, concentration, bioburden, endotoxin)

5.2 Sample Collection

  1. Use pre-sterilized, labeled containers with tamper-evident seals.
  2. Wear appropriate PPE and follow aseptic technique where applicable.
  3. Record time, volume, operator initials, and equipment ID in Annexure-1.
  4. Ensure homogenous mixing before sampling from bulk pools or intermediate holds.

5.3 Sample Handling and Transfer

  1. Store samples at defined temperatures (e.g., 2–8°C) and transfer to QC within defined hold time (e.g., 2 hours).
  2. Log sample transfer details in Annexure-2 and maintain chain of custody.

5.4 Testing and Data Recording

  1. QC to test samples using validated methods as per PVP (e.g., SDS-PAGE, ELISA, pH, conductivity).
  2. Compare results to acceptance criteria for each parameter.
  3. Document and report all data with analyst sign-off and date.

5.5 Deviations and Investigations

  1. Any out-of-specification (OOS) or abnormal result must be documented as per deviation SOP.
  2. Initiate CAPA as required and include impact assessment on process validation conclusions.

5.6 Documentation and Archiving

  1. Attach original chromatograms, raw data sheets, and equipment log extracts to the validation batch record.
  2. Ensure traceability and retention as per regulatory requirement (minimum 5 years).

6. Abbreviations

  • DSP: Downstream Processing
  • PVP: Process Validation Protocol
  • CPP: Critical Process Parameter
  • OOS: Out of Specification

7. Documents

  1. DSP Sampling Record – Annexure-1
  2. Sample Transfer Log – Annexure-2
  3. QC Analysis Summary Sheet – Annexure-3

8. References

  • ICH Q8, Q9, Q10 – Pharmaceutical Development, Risk Management, Quality Systems
  • FDA Process Validation: General Principles and Practices
  • WHO TRS 1004 – GMP for Biotherapeutics

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: DSP Sampling Record

Date Time Stage Volume (mL) Container ID Operator
04/05/2025 10:15 Post Protein A 50 SMP-190-A Ajay Verma

Annexure-2: Sample Transfer Log

Sample ID Transferred To Temp (°C) Transfer Time Received By
SMP-190-A QC Lab 4 11:00 Sunita Reddy

Annexure-3: QC Analysis Summary Sheet

Sample ID Test Result Limit Analyst
SMP-190-A pH 6.9 6.5–7.5 Dr. Neha Rao
SMP-190-A Endotoxin 0.06 EU/mg ≤ 0.1 EU/mg Dr. Neha Rao

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Integrated chain of custody log and expanded sampling points Validation Protocol Alignment
See also  Biosimilars: SOP for Deviation Handling During Clone Development - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Ensuring SOP Alignment with Outsourced Logistics Providers for GMP Compliance
Next Post: Quality Assurance: SOP for Preparing Annual Product Quality Review (APQR) Reports – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version